[HTML][HTML] The evolving biomarker landscape for treatment selection in metastatic colorectal cancer
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …
important improvements in patient outcomes. However, it is still necessary to increase …
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
J Taieb, A Jung, A Sartore-Bianchi, M Peeters… - …, 2019 - epub.ub.uni-muenchen.de
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …
important improvements in patient outcomes. However, it is still necessary to increase …
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.
J Taieb, A Jung, A Sartore-Bianchi, M Peeters… - Drugs, 2019 - europepmc.org
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …
important improvements in patient outcomes. However, it is still necessary to increase …
[PDF][PDF] The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
J Taieb, A Jung, A Sartore‑Bianchi, M Peeters… - 2019 - core.ac.uk
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …
important improvements in patient outcomes. However, it is still necessary to increase …
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
J Taieb, A Jung, A Sartore-Bianchi, M Peeters… - DRUGS, 2019 - air.unimi.it
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …
important improvements in patient outcomes. However, it is still necessary to increase …
[HTML][HTML] The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
J Taieb, A Jung, A Sartore-Bianchi, M Peeters… - Drugs, 2019 - ncbi.nlm.nih.gov
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …
important improvements in patient outcomes. However, it is still necessary to increase …
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
J Taieb, A Jung, A Sartore-Bianchi, M Peeters… - …, 2019 - pubmed.ncbi.nlm.nih.gov
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …
important improvements in patient outcomes. However, it is still necessary to increase …
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.
J Taieb, A Jung, A Sartore-Bianchi, M Peeters… - Drugs, 2019 - search.ebscohost.com
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …
important improvements in patient outcomes. However, it is still necessary to increase …
The evolving biomarker landscape for treatment selection in metastatic colorectal cancer
J Taieb, A Jung, A Sartore Bianch, M Peeters… - 2019 - repositori.upf.edu
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …
important improvements in patient outcomes. However, it is still necessary to increase …
The evolving biomarker landscape for treatment selection in metastatic colorectal cancer
J Taieb, A Jung, A Sartore-Bianchi… - Drugs …, 2019 - repository.uantwerpen.be
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …
important improvements in patient outcomes. However, it is still necessary to increase …